Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.68 |
| ▸ | PTGES | O14684 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | PDE5A | O76074 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198881 | 0.94 | PTGS1 (0.80) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL8266070 | 0.92 | PTGS2 (0.80) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| Carbamic Acid SCHEMBL5859288 | 0.92 | PTGS1 (0.68) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| Sulfamide SCHEMBL7136410 | 0.92 | PTGS2 (0.78) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL15915380 | 0.92 | PTGS1 (0.68) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL6451398 | 0.89 | PTGS1 (1.00) | PTGS1PTGS2PDPK1MAPTSMN1; SMN2 | |
| SCHEMBL5426104 | 0.89 | PTGS2 (0.63) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL4587051 | 0.87 | PTGS2 (0.73) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL8265772 | 0.87 | PTGS2 (0.73) | PTGS1PTGS2CYP2C9PDPK1HDAC3 | |
| SCHEMBL27602805 | 0.87 | PTGS1 (0.82) | PTGS1PTGS2PDPK1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111499576-A | Preparation method of celecoxib impurity | 迪嘉药业集团有限公司 | 2020-08-07 | — | — | CN | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| CN-111499576-A | Preparation method of celecoxib impurity | 迪嘉药业集团有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111499576-A | Preparation method of celecoxib impurity | 迪嘉药业集团有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-7202367-B2 | Process for arylating or vinylating or alkynating a nucleophilic compound | RHODIA CHIMIE (FR) | 2007-04-10 | — | — | US | disclosed |
| US-7202367-B2 | Process for arylating or vinylating or alkynating a nucleophilic compound | RHODIA CHIMIE (FR) | 2007-04-10 | — | — | US | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1675585-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2006-07-05 | — | — | EP | disclosed |
| US-20050234239-A1 | Method of forming a carbon-carbon or carbon-heteroatom linkage | SHASUN PHARMA SOLUTIONS, INC. | 2005-10-20 | — | — | US | disclosed |
| CN-1668595-A | Method for forming carbon-carbon or carbon-heteroatom bonds | RHONE POULENC CHIMIE (FR) | 2005-09-14 | — | — | CN | disclosed |
| EP-1562914-A1 | NITRIC OXIDE RELEASING SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005037271-A2 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | TANABE SEIYAKU CO., LTD. (JP) | 2005-04-28 | — | — | WO | disclosed |
| EP-1509502-A1 | METHOD OF FORMING A CARBON-CARBON OR CARBON-HETEROATOM LINKAGE | RHODIA CHIMIE (FR) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004037798-A1 | NITRIC OXIDE RELEASING SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-05-06 | — | — | WO | disclosed |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | SHASUN PHARMA SOLUTIONS, INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003101966-A1 | METHOD OF FORMING A CARBON-CARBON OR CARBON-HETEROATOM LINKAGE | RHODIA CHIMIE (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234239-A1 | Method of forming a carbon-carbon or carbon-heteroatom linkage | AOC1, AOC3, NUDT1 | PTGS1 1096/4885PTGS2 965/4885CYP2C9 258/4885 |
| US-20030236413-A1 | Catalysis in presence of a metallic element, an imine ligand and nitrogen compound as chelating compound, forming a chemical intermediates in the agrochemical and pharmaceutical fields | ALK, INMT, ACHE | PTGS1 2593/4885PTGS2 2246/4885CYP2C9 24/4885 |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | PTGS1 558/4885PTGS2 594/4885CYP2C9 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.